The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass
Open accessAbstract
OBJECTIVE: It is often difficult to distinguish a benign pelvic mass from a malignancy and tools to help referring physician are needed. The purpose of this study was to validate the Risk of Ovarian Malignancy Algorithm in women presenting with a pelvic mass. METHODS: This was a prospective, multicenter, blinded clinical trial that included women who presented to a gynecologist, a family practitioner, an internist, or a general surgeon with an adnexal mass. Serum HE4 and CA 125 were determined preoperatively. A Risk of Ovarian Malignancy Algorithm score was calculated and classified patients into high-risk and low-risk groups for having a malignancy. The sensitivity, specificity, negative predictive value, and positive predictive value of the Risk of Ovarian Malignancy Algorithm were estimated. RESULTS: A total of 472 patients were evaluated with 383 women diagnosed with benign disease and 89 women with a malignancy. The incidence of all cancers was 15% and 10% for ovarian cancer. In the postmenopausal group, a sensitivity of 92.3% and a specificity of 76.0% and for the premenopausal group the Risk of Ovarian Malignancy Algorithm had a sensitivity of 100% and specificity of 74.2% for detecting ovarian cancer. When considering all women together, the Risk of Ovarian Malignancy Algorithm had a sensitivity of 93.8%, a specificity of 74.9%, and a negative predictive value of 99.0%. CONCLUSION: The use of the serum biomarkers HE4 and CA 125 with the Risk of Ovarian Malignancy Algorithm has a high sensitivity for the prediction of ovarian cancer in women with a pelvic mass. These findings support the use of the Risk of Ovarian Malignancy Algorithm as a tool for the triage of women with an adnexal mass to gynecologic oncologists. LEVEL OF EVIDENCE: II.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Moore, R. G., McMeekin, D. S., Brown, A. K., DiSilvestro, P., Miller, M. C., Allard, W. J., Gajewski, W., Kurman, R., Bast, R. C., & Skates, S. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.031 · Cited by 875
Self-citationThe HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.
Hellström, I., Raycraft, J., Hayden-Ledbetter, M. S., Ledbetter, J. A., Schummer, M., McIntosh, M. W., Drescher, C. W., Urban, N. D., & Hellström, K. E. (2003) · PubMed · Cited by 711
Moore, R. G., Brown, A. K., Miller, M. C., Skates, S., Allard, W. J., Verch, T., Steinhoff, M., Messerlian, G., DiSilvestro, P., Granai, C. O., et al. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.017 · Cited by 695
Self-citationWelsh, J. B., Zarrinkar, P. P., Sapinoso, L. M., Kern, S. G., Behling, C. A., Monk, B. J., Lockhart, D. J., Burger, R. A., & Hampton, G. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1176 · Cited by 654
Drapkin, R., von Horsten, H. H., Lin, Y., Mok, S. C., Crum, C. P., Welch, W. R., & Hecht, J. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3924 · Cited by 570
Hough, C. D., Sherman‐Baust, C. A., Pizer, E. S., Montz, F. J., Im, D. D., Rosenshein, N. B., Cho, K. R., Riggins, G. J., & Morin, P. J. (2000) · PubMed · Cited by 502
Comprehensive analysis of HE4 expression in normal and malignant human tissues
Galgano, M. T., Hampton, G. M., & Frierson, H. F. (2006) · Modern Pathology · doi:10.1038/modpathol.3800612 · Cited by 437
Effect of Surgeon Specialty on Processes of Care and Outcomes for Ovarian Cancer Patients
Earle, C. C., Schrag, D., Neville, B. A., Yabroff, K. R., Topor, M., Fahey, A., Trimble, E. L., Bodurka, D. C., Bristow, R. E., Carney, M., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj019 · Cited by 416
Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma
Engelen, M. J. A., Kos, H. E., Willemse, P. H. B., Aalders, J. G., de Vries, E. G. E., Schaapveld, M., Otter, R., & van der Zee, A. G. J. (2006) · Cancer · doi:10.1002/cncr.21616 · Cited by 305
Cited by
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-129 · Cited by 524
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer
Zhang, M., Cheng, S., Jin, Y., Zhao, Y., & Wang, Y. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188503 · Cited by 384
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-M., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0122 · Cited by 311
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Romero, I., & Bast, R. C. (2012) · Endocrinology · doi:10.1210/en.2011-2123 · Cited by 286
Kawahara, N., Miyake, R., Yamanaka, S., & Kobayashi, H. (2021) · Cancers · doi:10.3390/cancers13153829 · Cited by 18
Metadata
- Authors
- Moore, R. G., Miller, M. C., Disilvestro, P., Landrum, L. M., Gajewski, W., Ball, J. J., & Skates, S. J.
- Venue
- Obstetrics & Gynecology
- Published
- 2011-08
- Volume
- 118
- Issue
- 2
- Pages
- 280-288
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2071020286
- Cited by
- 308
- References
- 18
- FWCI
- 19.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass. https://app.cochat.ai/papers/10.1097/aog.0b013e318224fce2
- The paper
- Moore, R. G., Miller, M. C., Disilvestro, P., Landrum, L. M., Gajewski, W., Ball, J. J., & Skates, S. J. (2011). Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass. Obstetrics & Gynecology. https://doi.org/10.1097/aog.0b013e318224fce2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.